Acuity poised to begin AMD-drug trials

March 15, 2004

Philadelphia-Acuity Pharmaceuticals has raised $2.4 million in its first institutional round of financing to fund pre-clinical studies of Cand5, being developed for treating age-related macular degeneration (AMD).